605266.SH
JZJ Chain Drugstore Corp.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 16.46
−0.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.7B | 8.9B | 9.3B | 9.1B | 7.5B |
| Cost of Revenue | 5.6B | 5.7B | 6.0B | 5.8B | 4.8B |
| Gross Profit | 3.2B | 3.2B | 3.3B | 3.3B | 2.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 215.9M | 221.4M | 263.1M | 197.0M | 209.9M |
| Selling & Marketing Expense | 2.5B | 2.6B | 2.7B | 2.4B | 1.9B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.9B | 3.0B | 3.1B | 2.7B | 2.2B |
| Cost and Expenses | 8.5B | 8.7B | 9.1B | 8.6B | 7.0B |
| Operating Income (EBIT) | 213.1M | 210.1M | 176.1M | 522.1M | 445.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 210.0M | 207.2M | 168.9M | 522.7M | 440.7M |
| Income Tax Expense | 59.5M | 59.0M | 41.0M | 108.2M | 66.3M |
| Bottom Line | |||||
| Net Income | 150.6M | 148.1M | 128.1M | 414.4M | 374.3M |
| Earnings from Cont. Ops | 150.5M | 148.1M | 128.0M | 414.5M | 374.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 150.6M | 148.1M | 128.1M | 414.4M | 374.3M |
| Per Share | |||||
| Basic EPS | CN¥1.00 | CN¥1.00 | CN¥0.83 | CN¥2.69 | CN¥2.97 |
| Diluted EPS | CN¥1.00 | CN¥1.00 | CN¥0.83 | CN¥2.68 | CN¥2.96 |
| Revenue Per Share | CN¥58.20 | CN¥60.22 | CN¥60.13 | CN¥58.94 | CN¥59.63 |
| Shares | |||||
| Basic Shares Outstanding | 149.8M | 148.1M | 154.4M | 154.1M | 126.0M |
| Diluted Shares Outstanding | 149.8M | 148.1M | 154.4M | 154.1M | 126.0M |
| Profitability Metrics | |||||
| EBITDA | — | 445.3M | 403.9M | 719.7M | 601.0M |
| D&A | — | 235.2M | 227.8M | 197.6M | 155.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026